Canaccord analyst William Plovanic raised the firm’s price target on TriSalus Life Sciences (TLSI) to $12 from $11 and keeps a Buy rating on the shares. The firm said they continue to be bullish on the Med-Tech sector heading into 2026. They point to strong underlying demand from an aging population, a focus on acute healthcare needs, the healthy pace of M&A, and a market that is receptive to IPOs as the foundation for our belief in our positive outlook in the upcoming year.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI:
- TriSalus Life Sciences: Strong Growth Prospects and Strategic Developments Reinforce Buy Rating
- TriSalus Life Sciences: Strong Revenue Growth and Strategic Initiatives Drive Buy Rating
- Trisalus Life Sciences Reports Strong Earnings Amid Challenges
- TriSalus Life Sciences: Promising Growth and Strategic Expansions Justify Buy Rating
- TriSalus Life Sciences Reports Strong Revenue Growth